👍 Polycab's impressive growth continued into Q3
👍 Revenue rose 24% QOQ
👍 Wires & Cables revenue jumped 21% on the back of one large size export order
👍 Fast Moving Electrical Goods segment sales jumped 34% on the back of strong volume growth
👍 A pick-up in project execution drove the revenue in EPC
👎 Significant jump in advertising & marketing expense hit margins
👍 Lower corp tax rate aided the bottomline
👎 The domestic demand scenario remain sluggish
👍 Eyeing growth thru increased penetration in export markets
👍 Undertaking multiple brand development initiatives to penetrate the domestic market
👍 The ad spends wud remain high, but the economies of scale should aid the margin improvement in coming qtrs
👍 For W&C, the mgt expects the margins to be in the broad range of 11-13 percent.
👉Polycab revenue growth is mainly on account of large export order (1,000+ crores), which is expected to complete by Q1 FY21
👉The Biz could face some headwinds on growth front post the completion of export order
Source: Moneycontrol-research
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The Journey of Vini Costmetics
✍️1985: Darshan Patel joins his father's co Paras Pharmaceuticals
✍️1994: Launched Krack which was an overnight success
✍️1996-2000: Launched a range of products(D-Cold, Borosoft,Ring Guard,Itch Guard)
✍️2002: Launched Livon-IND's 1st hair detangler
✍️2005: Set Wet hairstyling gel is launched and later a deodrant under the same brand name
✍️2006: Patel exits Paras. He sold his 24% stake to Actis Capital for $43 Mn
✍️2007: Registered Vini Costmetics and spend the next couple of years doing consumer research
✍️2010: Vini Costmetics was launched; started selling pharma products; WhiteTone was launched; Paras Pharmaceuticasl was acquired by Reckitt Benckiser Group for INR 3260 Crs
✍️2011: Launched Fogg deodorants; Bay Capital came on board, investing 30 Crs
Aurobindo CMP 868
The company is developing:
✍️14 Biosimilars (5 of these expected to launch by FY25 with a US$20 market size)
✍️8 inhalers (US market size is >$10 Bn)
✍️Pneumcoccal Conjugate Vaccine (US$6.2 bn global market size)
✍️3 depot injectables (US$3.3 bn market size)
Co also developing 50 Other Complex generics
✍️Peptides (US$14.5 Bn Mkt size-Global $2.5 bn size for 5 filed ANDAs and Global $12bn for 10 under development)
✍️Topicals (US$4 Bn Mkt size-26 products under development currently out of total 37 products identified for development)
✍️Transdermal patches (US$3 Bn Global Mkt size) : 8 products under development (Clinical trials to begin for the 1st product in FY21)
✍️Nasals (US$1.3 Bn Mkt size) : 1 approved + 4 under development (Filing will be done over the course of next 3 yrs) #Aurobindopharma #Growth
✍️IND's Renewable Energy sector is world's 4th most attractive RE Mkt
✍️Globally, Cost to generate Solar & Wind Energy dropped by 90% & 70% in past 10 yrs
✍️Costs almost at par with NG
✍️RE is estimated to comprise ~60% of IND’s installed power capacity by 2030 (~24% at present)
✍️Global Investments in RE: $282 Bn in 2019
✍️45% cming frm China, who aims to get 62% energy via RE in nxt 3 yrs
✍️By 2040, IND aims to generate ~49% of total Electricity frm RE
✍️FDI inflow in the Indian non-conventional “energy sector” stood at $9.22B in last 10 years
✍️More than $42B has been invested in IND’s “RE” sector since 2014
✍️Estimated to attract investment ~$80B in nxt 4 yrs
✍️The past 9 months have slowed the Solar Energy installations by 80% v/s 2019 due to Covid
✍️2020-Cumulative solar capacity is ~37 GW
✍️2022-Tgt is 100 GW
Valiant Organics CMP 2795
✍️A Specialty Chemical Manufacturing Company.
✍️The products of the company find several applications mainly in the agro-chemical, pharmaceuticals, rubber, dyes, pigment & in the making of veterinary drugs
✍️Fully integrated manufacturing facilities
✍️Revenue: Domestic 85% & Export 15%
(Agro 40%,Specialty 30%,Dyes+Pigments 20%,API 10%)
✍️Rev. share from API is likely to increase in coming yrs
✍️One of the most competitive producers of Chlorination, Ammonolysis,Acylation,Hydrogenation & Methoxylation based specialty products
✍️Inorganic growth & organic capital expansion without much increase in Debt Equity
✍️Leveraging a de-risked biz model
✍️The synergistic acquisition of Amarjyot chemical ltd last year
✍️Ability to forward integrate by adding high-margin & high value products to maximise growth
IndusInd Bank CMP 380
✍ Stock fell frm 2038 high to 235
✍ Decreasing deposits
✍ Rising bad loans
✍ High exposure to telecom companies & NBFCs
✍ Exit of a long-time CEO
✍ Crisis at #yesbank has put question mark on rest of the private lenders
✍ Stock corrected 68% in March
Journey from 2035 to 235
✍ Dec 2017 - RBI imposes INR 3 Crs penalty for under-reporting of FY16 NPAs
✍ Apr 2018 - Reports divergence in FY17 NPAs of INR 1350 Crs frm RBI's estimates
✍ Sep 2018 - Discloses exposure of INR 3000 Crs to IL&FS, a crisis-ridden NBFC #IndusindBank
✍ July 2019 - Completes merger with Bharat Financial Inclusion
✍ Jan 2020 - Posts disappointing Q3, provisions up by 72%, gross NPAs more than double YoY, asset quality worsens, Mr Sobti set to retire in Mar'20
✍ Feb 2020 - Moody's downgrades Outlook to Negative from Stable
The API Industry
✍️ The backbone of India pharma industry is the bulk drug industry
✍️ India has highest no. of US FDA approved plants (665) outside of the US
✍️ India has 44% of global abbreviated new drug applications (ANDA)
✍️ India needs to proactively boost the API Industry
✍️ The Indian pharma industry is the world's 3rd largest in terms of vol
✍️ India's API industry is ranked the 3rd largest in the world
✍️ India fulfils 20% of global demand for generic medicines in terms of Vol & supplies over 60% of global demand of various vaccines & ARV drugs
✍️ Indian bulk drug industry has grown at CAGR of 8.6% over 2016-2020. It is further expeacted to grow at similar CAGR during 2020-2024
✍️ The import of APIs has risen at a CAGR of 8.3% from 2012-2019
✍️ Bulk drug import reached a value of INR ~249 billion in 2019